on ADOCIA (EPA:ADOC)
Adocia Secures €7 Million to Extend Cash Runway
Adocia, a biopharmaceutical firm specializing in diabetes and obesity treatment, has secured a €7 million financing. This includes a €3 million capital increase through the issuance of 1,477,934 new shares at €2.04 each. Notably, company directors and a select group of historical investors participated.
The financing also involves a €4 million increase in the shareholder loan agreement with Vester Finance. This strategic move extends Adocia's cash runway to Q1 2028, targeting a $20 million milestone payment upon BC Lispro's approval in China, potentially extending runway to 2029.
The funds support technology promotion, manufacturing, and clinical development, removing previous uncertainties about Adocia's financial future. The new shares will begin trading on October 22, 2026, on Euronext Paris.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ADOCIA news